Bryan M. Reasons - 03 Jun 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
03 Jun 2021
Net transactions value
$0
Form type
4
Filing time
04 Jun 2021, 20:09:48 UTC
Previous filing
17 May 2021
Next filing
20 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Stock Option (Right to Buy) Award $0 +12,250 $0.000000 12,250 03 Jun 2021 Common Stock 12,250 $21.90 Direct F1, F2
transaction ACRS Restricted Stock Units Award $0 +3,356 $0.000000 3,356 03 Jun 2021 Common Stock 3,356 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy.
F2 The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date.
F3 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F4 The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date.